STATEN ISLAND, NY--(Marketwired - Nov 5, 2013) - Calmare Pain Relief Solutions (the "Company"), a chronic pain treatment medical practice, will increase its Calmare Pain Therapy clinic network by 70% in the Tri-state area in 2014. This expansion is in response to the U.S. Food and Drug Administration's (FDA) position regarding the benefits of using a non-narcotic solution for the relief of chronic pain. This position was highlighted in a recent New York Times article entitled "FDA Shift on Painkillers was Years in the Making."
With the increased acceptance of Calmare Pain Therapy by nationwide insurance companies, there has been an increase in new, chronic pain patient visitors to the Calmare Pain Relief Solutions' network of clinics. Their search for a non-invasive and non-narcotic pain relief regimen has resulted in the Company's redesigned corporate website. The site now offers chronic pain sufferers a web portal that houses a repository of information on the Calmare technology (commonly known as "Scrambler" technology). Visitors can view media reports and videos on the potential benefits gained from this alternative therapy versus a traditional biochemical solution. They can also read articles and research documents that may assist patients and healthcare providers in assessing the benefits of this technology.
"We wanted to offer patients and insurance companies a very informative website on the Calmare pain relief therapy," said David J. Palmieri, healthcare consultant to Calmare Pain Relief Solutions. "We often get requests for well-referenced information from patients and insurance providers and our new website is a direct response to those requests."
It has been very hard to prevent and treat CIPN because a
variety of drugs and supplements including glutamine, vitamin
E, and glutathione have been disappointing. A recent study
of a topical combination of the drugs baclofen, amitriptyline,
and ketamine (which some doctors actually recommend) for
treating CIPN showed some benefi t for sensory and motor
neuropathy. Another study showed some promise for a
patient-specifi c electro stimulation device (MC5-A Calmare;
Competitive Technologies, Wakefi eld, RI). Th is Calmare®
medical device is being further tested
currently. Th is device sends a no-pain message to the nerve
from surface electrodes applied to the skin in the area of the
patient’s pain. Next, the perception of pain is apparently
cancelled when the no-pain message replaces that of pain, by
utilizing the same pathway through the surface electrodes. If it
sounds a little confusing well it is but think of it like a message
distorting device. Th e average treatment time is from 20-
60 minutes. It sounds interesting and I really hope it works
because CIPN needs help now!